Tilos Therapeutics would be acquired by Merck for up to $773 million to expand the latter's pipelines in cancer, fibrosis, and autoimmune diseases. Tilos' pipelines include therapies that target latent TGFβ complex.
Merck buys Tilos to expand antibody pipelines
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.